Forbion is a stage-agnostic venture capital firm investing across all stages of biopharmaceutical drug development, from early company creation to later clinical-stage growth. Their core thesis focuses on backing science-led therapeutics and sustainable solutions that maximize patient impact. What makes Forbion unique is its dual-fund model (Ventures + Growth vehicles) and its close alignment with strategic pharma LPs like Eli Lilly, letting them internally spin out, build, and continuously back high-conviction biotech winners without losing ownership stakes to external late-stage competitors.